{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:45:31Z","timestamp":1791013531661,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.clinthera.2005.11.013","type":"journal-article","created":{"date-parts":[[2005,12,22]],"date-time":"2005-12-22T18:48:05Z","timestamp":1135277285000},"page":"1671-1684","source":"Crossref","is-referenced-by-count":25,"title":["Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"John","family":"Berry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2005.11.013_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1309\/4WV79N2GHJ3X1841","article-title":"Immunohistochemistry of estrogen and progesterone receptors reconsidered: Experience with 5,993 breast cancers","volume":"123","author":"Nadji","year":"2005","journal-title":"Am J Clin Pathol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib3","first-page":"5149","article-title":"The curability of breast cancer and the treatment of advanced disease","volume":"31","author":"Guarneri","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clinthera.2005.11.013_bib4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.0001-6349.2004.00562.x","article-title":"Aromatase inhibitors: Possible future applications","volume":"83","author":"Karaer","year":"2004","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib5","first-page":"510","article-title":"Are all aromatase inhibitors the same? A review of the current evidence","volume":"13","author":"Janicke","year":"2004","journal-title":"Breast"},{"issue":"Suppl 14","key":"10.1016\/j.clinthera.2005.11.013_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0093-7754(03)00305-1","article-title":"Pharmacokinetics of third-generation aromatase inhibitors","volume":"30","author":"Lonning","year":"2003","journal-title":"Semin Oncol"},{"issue":"Suppl 14","key":"10.1016\/j.clinthera.2005.11.013_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0093-7754(03)00303-8","article-title":"Aromatase inhibitor development and hormone therapy: A perspective","volume":"30","author":"Brodie","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2005.11.013_bib8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/jnci\/djh191","article-title":"Tamoxifen: Dr. Jekyll and Mr. Hyde?","volume":"96","author":"Hayes","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2005.11.013_bib9","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: An overview of the randomised trials","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2005.11.013_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0960-0760(03)00378-9","article-title":"Breast cancer prevention-clinical trials strategies involving aromatase inhibitors","volume":"86","author":"Goss","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.breast.2004.09.002","article-title":"Aromatase inhibitors-extending the benefits of adjuvant therapy beyond tamoxifen","volume":"13","author":"Smith","year":"2004","journal-title":"Breast"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib12","first-page":"S6","article-title":"Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancerin postmenopausal women: The IMPACT trial","volume":"82","author":"Smith","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2005.11.013_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1359-6349(04)90649-0","article-title":"Efficacy of PReOperative Arimidex (anastrozole) Compared with Tamoxifen (PROACT) as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer","volume":"2","author":"Cataliotti","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2005.11.013_bib14","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1023\/A:1013128213451","article-title":"Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study","volume":"12","author":"Eiermann","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2005.11.013_bib15","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2001.19.18.3808","article-title":"Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and\/or ErbB-2-positive, estrogen receptor-positive primarybreast cancer: Evidence from a phase III randomized trial","volume":"19","author":"Ellis","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.11.013_bib16","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2005.11.013_bib17","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses","volume":"98","author":"Baum","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2005.11.013_bib18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib19","first-page":"S3","article-title":"BIG 1\u201398: A prospective randomized double blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer","volume":"14","author":"Th\u00fcrlimann","year":"2005","journal-title":"Breast"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib20","first-page":"S6","article-title":"Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment","volume":"82","author":"Boccardo","year":"2003","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib21","first-page":"S7","article-title":"Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combinedresults from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial","volume":"88","author":"Jakesz","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2005.11.013_bib22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib23","first-page":"S7","article-title":"The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis","volume":"88","author":"Coombes","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2005.11.013_bib24","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for earlystage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2005.11.013_bib25","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTGMA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2005.11.013_bib26","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma","volume":"92","author":"Bonneterre","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2005.11.013_bib27","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.11.013_bib28","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or ArimidexRandomized Group Efficacy and Tolerability study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib29","first-page":"6S","article-title":"First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)\u2014arandomized phase III trial of the EORTC Breast Group","volume":"22","author":"Paridaens","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.11.013_bib30","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.11.013_bib31","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival andupdate of efficacy from the International Letrozole Breast Cancer Group","volume":"21","author":"Mouridsen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.11.013_bib32","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<730::AID-CNCR10>3.0.CO;2-0","article-title":"A phase III trial comparing anastro zole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate inpostmenopausal women with advanced breast carcinoma","volume":"79","author":"Buzdar","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2005.11.013_bib33","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7","article-title":"Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based ona combined analysis of data from two mature phase III trials","volume":"83","author":"Buzdar","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2005.11.013_bib34","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","article-title":"Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase IIIrandomized double-blind trial","volume":"18","author":"Kaufmann","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.11.013_bib35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1998.16.2.453","article-title":"Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy andtolerability compared with megestrol acetate","volume":"16","author":"Dombernowsky","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.11.013_bib36","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.20.3.751","article-title":"Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated ina randomized, crossover study","volume":"20","author":"Geisler","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.11.013_bib37","series-title":"Program and abstracts of the 38th Annual Meeting of the American Society of Clinical Oncology","article-title":"Randomized comparative study on estrogen suppression induced by 3 different aromatase inhibitors in postmenopausal patients with advanced breast cancer","author":"Bernardi","year":"2002"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib38","article-title":"Is there an optimal duration of neoadjuvant letrozole therapy?","volume":"88","author":"Renshaw","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2005.11.013_bib39","first-page":"10S","article-title":"BIG 1\u201398: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer","volume":"23 Suppl 6","author":"Th\u00fcrlimann","year":"2005"},{"key":"10.1016\/j.clinthera.2005.11.013_bib40","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1200\/JCO.2001.19.22.4209","article-title":"Sequential ta moxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results ofan Italian Cooperative Study","volume":"19","author":"Boccardo","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.11.013_bib41","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","article-title":"American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptorpositive breast cancer: Status report 2004","volume":"23","author":"Winer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.11.013_bib42","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/S0959-8049(03)00630-0","article-title":"An open randomized trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole andanastrozole","volume":"39","author":"Rose","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2005.11.013_bib43","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/00000421-200308001-00007","article-title":"Examining quality of life issues in relation to endocrine therapy for breast cancer","volume":"26","author":"Thomas","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.11.013_bib44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clon.2004.06.023","article-title":"Giving patients a choice improves quality of life: A multi-centre, investigator-blind, randomised, crossover study comparing letrozole withanastrozole","volume":"16","author":"Thomas","year":"2004","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2005.11.013_bib45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.9-suppl_3-20","article-title":"Overcoming endocrine therapy resistance by signal transduction inhibition","volume":"9","author":"Ellis","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2005.11.013_bib46","doi-asserted-by":"crossref","first-page":"889s","DOI":"10.1158\/1078-0432.889s.11.2","article-title":"Combinations of endocrine and biological agents: Present status of therapeutic and presurgical investigations","volume":"11","author":"Johnston","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib47","article-title":"Microarray analysis of sequential tumour biopsies from patients re ceiving neoadjuvant therapy is able to distinguish sub-populations of breastcancers with differential response to the aromatase inhibitor, letrozole","volume":"88","author":"Miller","year":"2004","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib48","article-title":"Early changes in tumour Ki67 expression differentiate for pathological (but not clinical) response in breast cancers treated neo-adjuvantly with letrozole","volume":"88","author":"Anderson","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2005.11.013_bib49","series-title":"Nolvadex [package insert]","year":"2003"},{"key":"10.1016\/j.clinthera.2005.11.013_bib50","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2005.11.013_bib51","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/978-3-642-55647-0_9","article-title":"Aromatase inhibitors in prevention-data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial and the design of IBIS-II (the secondInternational Breast Cancer Intervention Study)","volume":"163","author":"Cuzick","year":"2003","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.clinthera.2005.11.013_bib52","author":"National Cancer Institute of Canada"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib53","article-title":"Reduction in breast epithelial cell proliferation after six months of letrozole in high risk women on hormone replacement therapy with randomperiareolar fine needle aspiration evidence of atypia","volume":"88","author":"Fabian","year":"2004","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib54","first-page":"59","article-title":"Adjuvant endocrine therapies for pre\/perimenopausal women","volume":"14","author":"Pritchard","year":"2005","journal-title":"Breast"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib55","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0960-9776(03)80140-6","article-title":"Zoledronic acid prevents bone mineral density loss in premenopausal women receiving adjuvant treatment for hormone receptor-positive breast cancer:Preliminary results of a randomized, multicenter trial of zoledronic acid in patients receiving anastrozole or tamoxifen in combination with goserelin","volume":"12","author":"Hausmaninger","year":"2003","journal-title":"Breast (Scotland)"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib56","article-title":"Zoledronic acid (ZA) for prevention of cancer-treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): Preliminary results of the Z-FAST trial","volume":"88","author":"Brufsky","year":"2004","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.11.013_bib57","article-title":"Effect of letrozole versus placebo on bone mineral density in women completing 5 years of adjuvant tamoxifen: NCIC CTG MA.176","volume":"88","author":"Perez","year":"2004","journal-title":"Breast Cancer Res Treat"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805002924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805002924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T20:17:15Z","timestamp":1683317835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291805002924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S0149291805002924"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.11.013","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.8068.465556","asserted-by":"object"}]},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}